Simon Lichtiger

9.4k total citations · 4 hit papers
64 papers, 6.9k citations indexed

About

Simon Lichtiger is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Simon Lichtiger has authored 64 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Genetics, 36 papers in Epidemiology and 20 papers in Surgery. Recurrent topics in Simon Lichtiger's work include Inflammatory Bowel Disease (47 papers), Microscopic Colitis (30 papers) and Immunodeficiency and Autoimmune Disorders (11 papers). Simon Lichtiger is often cited by papers focused on Inflammatory Bowel Disease (47 papers), Microscopic Colitis (30 papers) and Immunodeficiency and Autoimmune Disorders (11 papers). Simon Lichtiger collaborates with scholars based in United States, Belgium and Canada. Simon Lichtiger's co-authors include Asher Kornbluth, William J. Sandborn, Paul Rutgeerts, Stephen B. Hanauer, Robert H. Diamond, C. Janneke van der Woude, Gerassimos J. Mantzaris, Geert D’Haens, Daniel Rachmilewitz and Kezhen L. Tang and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Simon Lichtiger

62 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

2010 2.3k citations Jean‐Frédéric Colombel, William J. Sandborn et al. New England Journal of Medicine profile →
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy

1994 1.3k citations Simon Lichtiger, D. H. Present et al. New England Journal of Medicine profile →
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

2012 838 citations William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine profile →
Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment

2016 355 citations Jordan E. Axelrad, Simon Lichtiger et al. World Journal of Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Lichtiger United States	25	5.3k	4.1k	2.0k	1.4k	665	64	6.9k
Walter Reinisch Austria	32	5.3k 1.0×	4.1k 1.0×	2.0k 1.0×	1.8k 1.3×	538 0.8×	71	7.2k
Ian Arnott United Kingdom	36	4.0k 0.8×	3.1k 0.7×	1.9k 0.9×	1.0k 0.7×	544 0.8×	132	5.4k
Jean‐Louis Dupas France	32	3.5k 0.7×	3.0k 0.7×	2.0k 1.0×	876 0.6×	466 0.7×	112	5.4k
Jean–Frédéric Colombel France	35	7.0k 1.3×	5.5k 1.3×	2.7k 1.3×	1.6k 1.1×	951 1.4×	75	8.9k
David Laharie France	42	3.8k 0.7×	3.4k 0.8×	1.7k 0.8×	1.0k 0.7×	435 0.7×	207	5.8k
Russell D. Cohen United States	47	6.7k 1.2×	5.2k 1.3×	2.7k 1.3×	1.6k 1.1×	641 1.0×	210	9.0k
Milan Lukáš Czechia	33	4.3k 0.8×	3.2k 0.8×	1.6k 0.8×	1.9k 1.4×	350 0.5×	156	6.0k
Pia Munkholm Denmark	40	5.3k 1.0×	4.0k 1.0×	2.5k 1.2×	842 0.6×	952 1.4×	110	7.2k
Pieter Stokkers Netherlands	45	4.0k 0.7×	2.5k 0.6×	2.2k 1.1×	1.4k 1.0×	574 0.9×	133	6.4k
Gerassimos J. Mantzaris Greece	41	8.0k 1.5×	6.3k 1.5×	3.4k 1.7×	1.9k 1.3×	1.1k 1.6×	145	10.5k

Countries citing papers authored by Simon Lichtiger

Since Specialization

Citations

This map shows the geographic impact of Simon Lichtiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Lichtiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Lichtiger more than expected).

Fields of papers citing papers by Simon Lichtiger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Lichtiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Lichtiger. The network helps show where Simon Lichtiger may publish in the future.

Co-authorship network of co-authors of Simon Lichtiger

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Lichtiger. A scholar is included among the top collaborators of Simon Lichtiger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Lichtiger. Simon Lichtiger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Verstockt, Bram, Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2023). The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn s and Colitis. 18(5). 762–772. 6 indexed citations

Faye, Adam S., Timothy Wen, Ashwin N. Ananthakrishnan, et al.. (2019). Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology. 18(5). 1133–1141.e3. 49 indexed citations

Kumar, Shria, et al.. (2019). Changes in Fecal Calprotectin Reflect Clinical Response in Treatment of an Acute Flare of Inflammatory Bowel Disease. 2(2). 18–22. 1 indexed citations

Nobel, Yael R., Jordan E. Axelrad, Suzanne K. Lewis, et al.. (2018). Stool PCR for Gastrointestinal Pathogens in Patients With and Without Immune-Mediated Intestinal Diseases. Digestive Diseases and Sciences. 63(4). 996–1002. 9 indexed citations

Axelrad, Jordan E., Andrew Joelson, Peter H.R. Green, et al.. (2018). Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. The American Journal of Gastroenterology. 113(10). 1530–1539. 68 indexed citations

Axelrad, Jordan E., Andrew Joelson, Yael R. Nobel, et al.. (2017). Enteric Infection in Relapse of Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 23(6). 1034–1039. 32 indexed citations

Axelrad, Jordan E., Simon Lichtiger, & Amrita Sethi. (2017). Treatment of Crohn’s Disease Anastomotic Stricture With a Lumen-apposing Metal Stent. Clinical Gastroenterology and Hepatology. 16(3). A25–A26. 21 indexed citations

Axelrad, Jordan E., Simon Lichtiger, & Vijay Yajnik. (2016). Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World Journal of Gastroenterology. 22(20). 4794–4794. 355 indexed citations breakdown →

Ferrante, Marc, Jean‐Frédéric Colombel, William J. Sandborn, et al.. (2013). Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC. Gastroenterology. 145(5). 978–986.e5. 135 indexed citations

10.

Sandborn, William J., Christopher Gasink, Marion Blank, et al.. (2012). Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. New England Journal of Medicine. 367(16). 1519–1528. 838 indexed citations breakdown →

11.

Murphy, Seamus, et al.. (2008). Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease. The American Journal of Gastroenterology. 103(4). 937–943. 76 indexed citations

12.

Swaminath, Arun, Thomas Ullman, Michael Rosen, et al.. (2008). Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab‐treated and naïve patients. Alimentary Pharmacology & Therapeutics. 29(3). 273–278. 33 indexed citations

13.

Lichtiger, Simon. (2008). Treatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporine. Inflammatory Bowel Diseases. 15(1). 141–142. 12 indexed citations

14.

Nilubol, Naris, Ellen Scherl, Stephen R. Gorfine, et al.. (2007). Mucosal Dysplasia in Ileal Pelvic Pouches After Restorative Proctocolectomy. Diseases of the Colon & Rectum. 50(6). 825–831. 30 indexed citations

15.

Swaminath, Arun & Simon Lichtiger. (2007). Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohnʼs colitis. Inflammatory Bowel Diseases. 14(2). 213–216. 73 indexed citations

16.

Cheifetz, Adam S., Asher Kornbluth, Peter Legnani, et al.. (2006). The Risk of Retention of the Capsule Endoscope in Patients with Known or Suspected Crohn's Disease. The American Journal of Gastroenterology. 101(10). 2218–2222. 275 indexed citations

17.

Nilubol, Naris, et al.. (2001). Ulcerative colitis and sarcoidosis.. PubMed. 68(6). 400–2. 12 indexed citations

18.

Present, Daniel H. & Simon Lichtiger. (1994). Efficacy of cyclosporine in treatment of fistula of crohn's disease. Digestive Diseases and Sciences. 39(2). 374–380. 190 indexed citations

19.

Lichtiger, Simon, D. H. Present, Asher Kornbluth, et al.. (1994). Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy. New England Journal of Medicine. 330(26). 1841–1845. 1267 indexed citations breakdown →

20.

Meyers, Samuel, et al.. (1988). Fecal ??1 -Antitrypsin as a Measure of Crohn??s Disease Activity. Journal of Clinical Gastroenterology. 10(5). 491–497. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact